2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5450 Comparative outcomes of autologous hematopoietic cell transplantation versus chimeric antigen receptor T-cell therapy in high-risk relapsed/refractory diffuse large B-cell lymphoma

Carmel A R Awadallah, MD, Maryam Khan, FCPS, MRCP2, Kashaf Awais3, Nabeeha Noor4, Shah Rukh5, Muhammad Kashif Amin, MD, MSc, FACP6, Drew R Nannini, DO, PhD7, Mehdi Hamadani, MD8, Al-Ola Abdallah, MD9, Joseph P McGuirk, DO10, Moazzam Shahzad, MD11, Muhammad Umair Mushtaq, MD12
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
7 University of Kansas Medical Center, Kansas City, Kansas, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
10 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
11 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
12 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States

Background:

Patients with diffuse large B-cell lymphoma (DLBCL) who are primary refractory to first-line therapy or relapse within 12 months represent a high-risk population with historically poor outcomes. CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has largely supplanted autologous hematopoietic cell transplantation (auto-HCT) for many of these patients, but direct comparisons in this high-risk subset remain limited. We compared outcomes between auto-HCT and CAR-T cell therapy using registry data.

Methods:

We performed a retrospective analysis using data from the Center for International Blood and Marrow Transplant Research (CIBMTR) under protocol P5958. We identified patients with relapsed/refractory (R/R) DLBCL who were primary refractory or relapsed within 12 months of first-line therapy and underwent either auto-HCT or CAR-T. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan–Meier method and compared by log-rank test. Cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were estimated using cumulative incidence functions accounting for competing risks and compared by Gray’s test. Cox proportional hazards models (OS, PFS) and Fine–Gray subdistribution hazard models (CIR, NRM) were used for univariable and multivariable analyses. Treatment group was forced into multivariable models along with covariates having univariable p < 0.10.

Results:

The high-risk cohort comprised 244 patients (auto-HCT n=181, CAR-T n=63). Median age was 60.6 years (41–65 years: 56.6%; >65 years: 33.2%); 62.3% were male and 72.1% were White. Most patients had advanced-stage disease (72.8%), extranodal involvement (70.5%), and elevated LDH (63.4% of those with available data). Median prior lines of therapy was 3. Among auto-HCT recipients, BEAM or BEAM-like conditioning was used in 76.2%. CAR-T products were evenly split between tisagenlecleucel (50.8%) and axicabtagene ciloleucel (49.2%); bridging therapy was given in 33.3%. Of 239 patients evaluable for time-to-event analyses (auto-HCT n=179, CAR-T n=60), 36-month OS was 74.9% with auto-HCT versus 62.6% with CAR-T (p=0.131), and 36-month PFS was 64.8% versus 38.9% (p=0.001). The 36-month CIR was substantially higher with CAR-T (52.6% vs 27.7%; Gray’s p=0.0005), while 36-month NRM was low and comparable (8.0% vs 7.5%; Gray’s p=0.68). On multivariable Cox analysis, treatment group was not independently associated with OS (auto-HCT vs CAR-T HR 0.53, 95% CI 0.26–1.11; p=0.094) or PFS (HR 0.62, 95% CI 0.33–1.18; p=0.144). Independent predictors of worse PFS were older age (HR 1.03 per year; p=0.019) and extranodal involvement (HR 2.42; p=0.008). On Fine–Gray analysis, CAR-T remained independently associated with higher relapse (SHR 1.88, 95% CI 1.03–3.44; p=0.04), as did extranodal involvement (SHR 1.81; p=0.042). No treatment effect was observed for NRM (CAR-T vs auto-HCT SHR 0.56, 95% CI 0.17–1.89; p=0.35); older age was the only independent predictor (SHR 1.08 per year; p=0.009). Among the 72 patients who died, disease relapse was the leading cause (59.7%), followed by infection (16.7%).

Conclusions:

In high-risk primary refractory or early-relapsing R/R DLBCL, CAR T-cell therapy was associated with significantly higher cumulative incidence of relapse and inferior unadjusted PFS compared with auto-HCT, while NRM remained low and comparable. The survival difference attenuated after multivariable adjustment, suggesting that selection and disease-biology factors contribute substantially. Relapse, rather than treatment-related mortality, was the dominant driver of failure in both arms. These CIBMTR registry data support that auto-HCT remains a relevant option in selected chemosensitive high-risk patients.

Carmel A R Awadallah, MD: No relevant conflicts of interest to declare.